| Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018 JM Loree, S Anand, A Dasari, JM Unger, A Gothwal, LM Ellis, ... Jama Oncology 5 (10), e191870-e191870, 2019 | 463 | 2019 |
| Representativeness of Black patients in cancer clinical trials sponsored by the National Cancer Institute compared with pharmaceutical companies JM Unger, DL Hershman, RU Osarogiagbon, A Gothwal, S Anand, ... JNCI cancer spectrum 4 (4), pkaa034, 2020 | 82 | 2020 |
| Sex representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic malignancies S Mendis, S Anand, JM Karasinska, A Dasari, JM Unger, A Gothwal, ... The oncologist 26 (2), 107-114, 2021 | 21 | 2021 |
| The Impact of Rehabilitation-oriented Virtual Reality Device in Patients With Ischemic Stroke in the Early Subacute Recovery Phase: Study Protocol for a Phase III, Single … N Ahmed, VAQ Mauad, O Gomez-Rojas, A Sushea, G Castro-Tejada, ... Journal of central nervous system disease 12, 1179573519899471, 2020 | 20 | 2020 |
| Underreporting of race/ethnicity in COVID-19 research K Raghav, S Anand, A Gothwal, P Singh, A Dasari, MJ Overman, ... International Journal of Infectious Diseases 108, 419-421, 2021 | 11 | 2021 |
| Comparison of physicians' knowledge regarding radiation exposure and risks in common radiological investigations--A cross-sectional study S Gothoskar, S Anand, P Walvekar International Journal of Medical Science and Public Health 7 (4), 305-311, 2018 | 4 | 2018 |
| Gender disparity in authorship of clinical trials leading to cancer drug approvals between 2008 and 2018: The glass ceiling of academic oncology. LO Chapman, JM Loree, S Anand, SR Mendis, LH McNeill, KPS Raghav, ... Journal of Clinical Oncology 40 (16_suppl), 11048-11048, 2022 | 2 | 2022 |
| Female representation in clinical trials leading to FDA cancer drug approvals for gastrointestinal (GI) cancers between 2008 to 2018. SR Mendis, S Anand, A Dasari, JM Unger, A Gothwal, LM Ellis, ... Journal of Clinical Oncology 38 (4_suppl), 809-809, 2020 | 2 | 2020 |
| Value appraisal of FDA approved cancer drugs over the past decade. R Huey, S Anand, JE Rogers, A Dasari, GR Varadhachary, A Gothwal, ... Journal of Clinical Oncology 37 (27_suppl), 115-115, 2019 | 2 | 2019 |
| A systematic review of surrogate endpoints (SEPs) for overall survival (OS) in metastatic colorectal cancer (mCRC). S Anand, D Tannenbaum, RA Horn, VK Morris, B Johnson, C Eng, ... Journal of Clinical Oncology 37 (15_suppl), e18206-e18206, 2019 | 2 | 2019 |
| On the underreporting of health-related quality of life and regulatory approval D Bhamidipati, S Anand, A Gothwal, K Raghav, MJ Overman Annals of Oncology 30 (4), 657-658, 2019 | 2 | 2019 |
| Racial representativeness of cancer clinical trials sponsored by the National Cancer Institute compared to pharmaceutical companies JM Unger, DL Hershman, RU Osarogiagbon, A Gothwal, S Anand, ... Cancer Research 80 (16_Supplement), 4344-4344, 2020 | | 2020 |
